Renowned luminaries in Personalized Medicine
Groundbreaking companies with emerging technologies
More than 1000 peers from around the globe
50 sessions in 3 parallel tracks

CO-HOSTED WITH
STANFORD HEALTH CARE, UCSF, & ORACLE

The Pharmaceutical Rx & Dx Development Process

We find ourselves in a fascinating time where the pharmaceutical industry both drives and embraces the learnings from personalized medicine both in their own in-house research activities as well as in collaborations with academic and clinical partners. This includes developing a deeper understanding of the biology underlying diseases (e.g. molecular understanding of targets and pathways), establishing causative correlations to ultimately derive predictive value on an individual patient level, gaining insights into translational understanding from pre-clinical models to clinical settings, or interrogating tissues (e.g. cancer biopsies) before and after treatment down to single cells, mRNA, and the protein level. The impact is on target validation, translation across species, and gaining predictive value to tailor medicines and treatment regimes to the specific patient subpopulations and individuals that have the highest probability of favorably responding to such interventions.

These exciting advancements are enabled by and tightly linked to the recent developments in computational capabilities: detection of patterns and trends in the wealth of data is crucial to validate  and clinically test hypotheses originally derived from preclinical models or related clinical insights (e.g. of predictive markers).

Drives behind these developments are patients, doctors and payors. Why? These days, new therapies need to demonstrate a clear and unambiguous advantage over existing treatments and standards of care, a critical hurdle keenly watched by payors and other stakeholders, to justify the costs and coverage. New therapies that “cure” a disease (e.g. Gilead’s Harvoni for hepatitis C treatment) versus drugs that just mitigate the disease, offer undeniable huge and unambiguous advantages which is in turn cited as justification for the often high costs of such treatments.  

SPEAKERS

Roger Perlmutter, M.D., Ph.D., President, Merck Research Laboratories

Roger M. Perlmutter, M.D., Ph.D., executive vice president and president of Merck Research Laboratories was formerly executive vice president and head of R&D at Amgen for twelve years. Read Full Bio

Sir Rory Collins, FRCP, FMEDSCI, Chief Executive, UK Biobank (Oxford)

Rory Collins was appointed Principal Investigator and Chief Executive of UK Biobank in September 2005. Rory qualified in medicine at St Thomas's Hospital Medical School, University of London, in 1981 and obtained BSc in statistics from George Washington University, Washington DC in 1977 and MSc in statistics from the University of Oxford in 1983. Read Full Bio

janus-dutkowski.png

Gini Deshpande, Ph.D., Founder and Chief Executive Officer, Numedii

Gini has 15+ years of experience translating cutting edge life sciences technologies into products and companies. As founder and CEO of NuMedii, she helped develop the company's core technology, built a stellar team, structured critical partnerships and raised the Company's initial rounds of financing from leading Bay Area VC firms. Read Full Bio

august-salvado.jpg

August Salvado, M.D., VP of Early Development, Strategy and Innovation, Novartis

Dr. Salvado received his medical degree from Tufts University School of Medicine. He is Board Certified in Internal Medicine, Hematology and Medical Oncology. From 1975 to 1996, he worked at Walter Reed Army Institute of Research in Washington, D.C. Read Full Bio

mike-townsend.jpg

Michael Townsend, Ph.D., Senior Scientist, Immunology, Tissue Growth and Repair Diagnostics Discovery, Genentech

Michael Townsend received his Ph.D. in Immunology from the MRC Laboratory of Molecular Biology in Cambridge, UK followed by a postdoctoral fellowship at the Harvard School of Public Health in Boston, MA. Read Full Bio

Scott Patterson, Ph.D., Vice President, Biomarker Sciences, Gilead Sciences

Scott Patterson, PhD, is Vice President, Biomarker Sciences in the R&D organization at Gilead Sciences, Inc, where he is responsible for development and implementation of biomarker and diagnostic strategies across all the company’s therapeutic areas. Read Full Bio

FEATURED SESSIONS

  • The Pharmaceutical Rx &Dx Development Process
    Session Chair: ?
  • Data Driven Rx &Dx
    Session Chair: Atul Butte, UCSF
  • Biomarker for Autoimmune Disease
    Session chair: Eric Sasso, Crescendo Bioscience
  • New Drug Development in Oncology: Faster, Cheaper and Better
    Session Chair: George Sledge, Stanford University
 
Web Analytics